Cancer gene therapy is a treatment investigation method that includes inserting foreign genetic material (DNA or RNA) into the cells of a patient to combat or prevent disease. Cancer gene therapy is performed to cure different types of cancers through somatic aberration in the host genome.
Due to the high success rate during preclinical and post-clinical trials, cancer gene therapy is gaining popularity and is anticipated to expand at a healthy growth rate over forecast years. The gene therapy market has changed over recent years with technological advances and is expected to witness further advancements in cancer treatment procedures in coming time. The global cancer gene therapy market is anticipated to grow at a prominent CAGR of 22% during forecast period.
North America accounted for a major share in the global cancer gene therapy market owing to well established healthcare infrastructure, and rising number of cancer patients across the region. Fuelled by rising awareness and increased government spending on strengthening cancer treatment infrastructure across major economies, Asia Pacific cancer gene therapy market is anticipated to be the fastest growing market during forecast period.
Major players operating in the global cancer gene therapy market include GlaxoSmithKline plc, Adaptimmune Therapeutics plc, Merck & Co., Inc., bluebird bio, Inc., Shanghai Sunway Biotech Co., Ltd, Celgene, SIBIONO, Anchiano Therapeutic, Achieve Life Sciences, Inc., and Synergene Active Ingredients Pvt. Ltd.
The report titled “Cancer gene therapy Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global cancer gene therapy market.
Furthermore, the report would reflect on the key developments, global & regional sales network, business strategies, security & exchange overview, research & development activities, production facilities, product portfolio, employee strength, and key executive, for all the players considered under the scope of study. For instance, GlaxoSmithKline plc reported revenues of US$ 40176.71 Million in 2018 and the segment and geographic analysis of the company indicates that Pharmaceuticals business segment is the dominating segment of the company, with the United States being the major revenue generating geography.
The global cancer gene therapy market is segmented based on therapy, end user and geography. Based on therapy, the global cancer gene therapy market is segmented into gene induced immunotherapy, oncolytic virotherapy and gene transfer. The Gene-induced immunotherapy is sub-segmented into cytokine gene delivery and tumour antigen gene delivery. The oncolytic virotherapy is sub-segmented into adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others.
Similarly, the Gene transfer therapy is further sub-segmented into naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun. Based on end user, the global cancer gene therapy market is segmented into hospitals, diagnostic centres and research institutes. Based on geography, the global cancer gene therapy market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
Additionally, the study provides in-depth analysis of individual company considered under the scope of study with a focus on all operating business segment, and would identify the segment of the company focusing on cancer gene therapy products and services. Further, market share of company in the global cancer gene therapy market would also be calculated. For instance, GlaxoSmithKline plc operates through three business segments namely Pharmaceuticals, Vaccines, and Consumer Healthcare.
Moreover, Pharmaceuticals business unit of the company deals with cancer gene therapy products, with a revenue contribution of US$ 22511.0 Million. The report study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the cancer gene therapy companies. Furthermore, the global cancer gene therapy market study would take into consideration the participants engaged throughout the ecosystem of the market, along with their contribution.
Product portfolio would focus on all the products and services under the cancer gene therapy business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global cancer gene therapy market arena.
For instance, in 2018, GlaxoSmithKline plc acquired Tesaro, an oncology focused Biotechnology Company based in Boston, which has a marketed oncology product and several pipeline assets with development potential. The key players in the global cancer gene therapy market are focused on developing advanced, effective and cost-efficient solutions in order to gain competitive edge in the global market.
Market Segmentation:
By Therapy
By End user
By Geography
Cancer gene therapy is a treatment investigation method that includes inserting foreign genetic material (DNA or RNA) into the cells of a patient to combat or prevent disease.
North America accounted for a major share in the global cancer gene therapy market owing to well established healthcare infrastructure, and rising number of cancer patients across the region.
The global Cancer Gene Therapy market is estimated to exhibit a CAGR of 22% in terms of revenue over the forecast period.
Major participants in the cancer gene therapy industry comprise GlaxoSmithKline plc, Adaptimmune Therapeutics plc, Merck & Co., Inc., bluebird bio, Inc., Shanghai Sunway Biotech Co., Ltd, Celgene, SIBIONO, Anchiano Therapeutic, Achieve Life Sciences, Inc., and Synergene Active Ingredients Pvt. Ltd.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved